Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Harpoon Therapeutics  (Stock symbol: HARP )

4000 Shoreline Court, Suite 250
So. San Francisco, CA 94080
USA
650-443-7400
Website Company Summary Management Team
Management

CEO: Gerald McMahon (12/31/2016)
General Management: Che-Leung Law (4/30/2017) ; Rachel Lester (9/30/2017) ; Rick Austin (6/30/2015) ; Natalie Sacks (10/1/2018)
Finance: Christopher Whitmore (7/31/2018) ; Georgia Erbez (10/7/2018)
Technology: Susan D. Dana Jones (7/31/2017) ; Holger Wesche (4/30/2015)
Former Employees: William Picht
Board

Outside board: (May no longer be on the board) Scott Myers (Bioclin Therapeutics Chairman of the Board) Luke Evnin (MPM Capital Managing Director) Julie Eastland (BioClin Therapeutics CFO) Patrick A. Baeuerle (MPM Capital Executive Partner) Mark Chin (Arix Bioscience investment manager) Jonathan Drachman (Seattle Genetics Chief Medical Officer) Ron M. Hunt (New Leaf Venture Partners Managing Director)
Former outside board: Lori Anne Kunkel (Pharmacyclics Former Chief Medical Officer)
Company

Business description: Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct™ (“TriTAC”), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon recently announced its second technology platform, ProTriTAC, that applies a prodrug concept to TriTAC in order to create T cell engagers that are designed to be preferentially active in the tumor microenvironment.
Capital

Rounds: 3
Recent Fundings: Nov 2018   May 2017
Capital raised: 130.0M
Last Round: 70.0M
Ownership: Public   Ipo Filing
Stock Symbol: HARP
VCs include: MPM Capital OrbiMed New Leaf Venture Partners ;  Arix Bioscience ;  Cormorant ;  Oncology Impact Fund
Corporate investors: Taiho Ventures

Last Tweets


 

Last Mentions


Overview
Record updated: Feb 2019
Sector: Biotech
Headcount: 26-50 as of Feb 2019
Rounds: 3
Recent Fundings: Nov 2018   May 2017
Capital Raised: 130.0M
Last Round: 70.0M
Ownership: Public   Ipo Filing
Stock Symbol: HARP